Lirafugratinib

DB18300InvestigationalSmall molecule

Lirafugratinib: Overview.

Mechanism: Pharmacologically active on Fibroblast growth factor receptor 2
Curator reviewed
Formula / weight: C₂₈H₂₄FN₇O₂ · 509.545 g/mol (avg)
Also known as: 2-Propenamide, N-[4-[4-amino-5-[3-fluoro-4-[(4-methyl-2-pyrimidinyl)oxy]phenyl]-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-2-methyl- · N-(4-(4-amino-5-(3-fluoro-4-((4-methylpyrimidin-2-yl)oxy)phenyl)-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)phenyl)methacrylamide · N-[4-(4-amino-5-{3-fluoro-4-[(4-methylpyrimidin-2- yl)oxy]phenyl}-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-6- yl)phenyl]-2-methylprop-2-enamide
Code names: RLY-4008

Resolves to

Compound

Structure

InChIKeyXOQVZSSDIQQUGO-UHFFFAOYSA-NSMILESCN1C2=NC=NC(N)=C2C(=C1C1=CC=C(NC(=O)C(C)=C)C=C1)C1=CC=C(OC2=NC=CC(C)=N2)C(F)=C1

Targets

What you can answer from here — as of September 16, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lirafugratinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.